NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally. NeuroPharm™ is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of matter claims regarding a psychedelic therapy enhancer for the…
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the special committee will discuss include, but limited to, a potential spin out of certain company assets. Currently,…
In mid-August, Mydecine released a corporate update that provided visibility into the projects that the team is working on as well as the recent advancements and achievements by the business. Going forward, Mydecine plans to continue to create shareholder value and position itself as a genuine leader in the functional…
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" “MIG” or the "Company"), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position Mydecine as a genuine leader in the ever-expanding fungi and psychedelic sectors. Through our leadership, we are positioning…
Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform. Mindleap™ is working towards contributing to the evolution of…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company's new Chief Marketing Officer ("CMO"). "When I was first contacted by Damon Michaels, the company's Chief Operations Officer,…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board. Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last…
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee. The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation Center in Denver,…